AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
ISONIAZID + RIFAPENTINE
9 registrations across 4 African markets— 8 active
Markets with ISONIAZID + RIFAPENTINE
🇺🇬Uganda
4 registrations
4 active
🌍WW
2 registrations
2 active
🇿🇼Zimbabwe
2 registrations
2 active
🇲🇼Malawi
1 registration
0 active
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| NONE TABLET, COATED; ORAL | 🇿🇼Zimbabwe | LUPIN LIMITED | active | Apr 2031 |
| ISONIAZID; RIFAPENTINE TABLET, COATED; ORAL | 🇿🇼Zimbabwe | MACLEODS PHARMACEUTICALS LIMITED | active | Dec 2028 |
| ISONIAZID+RIFAPENTINE 300/300MG TABLET TABLET | 🇲🇼Malawi | — | expired | Mar 2024 |
| ISONIAZID +
RIFAPENTINE ORAL SOLID
ORDINARY FILM-
COATED
TABLETS | 🇺🇬Uganda | MACLEODS PHARMACEUTICA LS LTD | active | — |
| ISONIAZID +
RIFAPENTINE ORAL SOLID
ORDINARY FILM-
COATED TABLETS | 🇺🇬Uganda | MACLEODS PHARMACEUTICA LS LTD | active | — |
| ISONIAZID +
RIFAPENTINE ORAL SOLID
ORDINARY FILM-
COATED TABLETS | 🇺🇬Uganda | MACLEODS PHARMACEUTICA LS LTD | active | — |
| Isoniazid/Rifapentine Tablet, Film-coated 300mg/300mg Tablet, Film-coated | 🌍WW | Lupin Ltd | active | — |
| ISONIAZID +
RIFAPENTINE ORAL SOLID
ORDINARY FILM-
COATED
TABLETS | 🇺🇬Uganda | MACLEODS PHARMACEUTICA LS LTD | active | — |
| Isoniazid/Rifapentine Tablet, Film-coated 300mg/300mg Tablet, Film-coated | 🌍WW | Macleods Pharmaceuticals Ltd | active | — |
ISONIAZID + RIFAPENTINE in Africa — Regulatory Overview
ISONIAZID + RIFAPENTINE is registered across 4 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Uganda, WW, Zimbabwe, Malawi. AfricaRegulatory refreshes this data daily from official government sources.
Of the 9 registrations, 8 (89%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.